How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

100 results for

Symlin

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Study of MiniMedâ„¢ 640G Insulin Pump With SmartGuardâ„¢ in Prevention of Low Glucose Events in Adults With Type 1 Diabetes

the study. Exclusion Criteria: Untreated Addison's disease, thyroid disorder, growth hormone deficiency, hypopituitarism or definite gastroparesis, per investigator judgment. Subject is using Pramlintide (Symlin) SGLT2 inhibitor, GLP agonist at time of screening. Renal failure defined by creatinine clearance <30 ml/min, as assessed by local lab test ≤ 3 months before screening or performed at screening at local lab. Hearing or vision impairment hindering perception of glucose display and alarms

2016 Clinical Trials

22. Day and Night Closed-loop in Young People With Type 1 Diabetes

of pramlintide (Symlin), or other non-insulin glucose lowering agents including sulphonylureas, biguanides, DPP4-Inhibitors, , GLP-1 analogues, SGLT-1/ 2 inhibitors at time of screening Shift work with working hours between 10pm and 8am Sickle cell disease, haemoglobinopathy, or has received red blood cell transfusion or erythropoietin within 3 months prior to time of screening Eating disorder such as anorexia or bulimia Employed by Medtronic Diabetes or with immediate family members employed by Medtronic

2016 Clinical Trials

23. Safety Evaluation of the Hybrid Closed Loop (HCL) System in Pediatric Subjects With Type 1 Diabetes

prior to screening resulting in a primary diagnosis of uncontrolled diabetes Subject 2-6 years of age has been hospitalized or has visited the ER in the 3 months prior to screening resulting in a primary diagnosis of uncontrolled diabetes Subject is currently abusing illicit drugs Subject is currently abusing marijuana. Subject is currently abusing prescription drugs Subject is currently abusing alcohol Subject is using pramlintide (Symlin), DPP-4 inhibitor, liraglutide (Victoza or other GLP-1

2016 Clinical Trials

24. Multi-center Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System at Home

glucocorticoids during the course of the study. Subject is actively participating in an investigational study (drug or device) wherein he/she has received treatment from an investigational study drug or investigational study device in the last 2 weeks Subject is currently abusing illicit drugs or marijuana Subject is currently abusing prescription drugs Subject is currently abusing alcohol Subject is using pramlintide (Symlin), SGLT2 inhibitors, GLP agonists, biguanides, DPP-4 inhibitors or sulfonylureas

2016 Clinical Trials

25. Safety of Overestimation of a Meal Insulin Bolus in the Context of Dual-hormone Closed-loop Operation

months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery. Pregnancy. Severe hypoglycemic episode within 1 month of screening. Agents affecting gastric emptying (Motilium®, Prandase®, Victoza®, Byetta® and Symlin®) as well as oral anti-diabetic agents (Metformin, SGLT-2 inhibitors and DPP-4 inhibitors) if not at a stable dose for 3 months. Otherwise, these medications are acceptable and will be kept stable during the entire protocol. Oral steroids unless patients present a low

2016 Clinical Trials

26. Improving Glycaemic Control in Malaysian Patients With Type 2 Diabetes Mellitus With Insulin Pump Therapy

on screening visit is > 180 mmHg Diastolic blood pressure on screening visit is > 110 mmHg Any other disease (eg active cancer under treatment) or condition including abnormalities found on the screening tests, that in the opinion of the Investigator, may preclude the patient from participating in the study Taking any medication prescribed for weight loss Alcohol or drug abuse, other than nicotine, at the Investigator's discretion Use of a Glucagon Like Peptide-1 agonist or pramlintide (Symlin®). Glucagon (...) Like Peptide-1 slows gastric emptying, thereby decreasing the rate of glucose absorption. Pramlintide (Symlin®) is a commercially available analogue of amylin, a synergistic partner to insulin. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number

2016 Clinical Trials

28. Safety of Overestimation of a Meal Insulin Bolus in the Context of Dual-hormone Closed-loop Operation

) or severe proliferative retinopathy as judged by the investigator. Recent (< 3 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery. Pregnancy. Severe hypoglycemic episode within 1 month of screening. Agents affecting gastric emptying (Motilium®, Prandase®, Victoza®, Byetta® and Symlin®) as well as oral anti-diabetic agents (Metformin, SGLT-2 inhibitors and DPP-4 inhibitors) if not at a stable dose for 3 months. Otherwise, these medications are acceptable and will be kept

2015 Clinical Trials

29. Home Testing of Day and Night Closed Loop With Pump Suspend Feature

to tolerate tape adhesive in the area of sensor placement Serious skin diseases (e.g. psoriasis vulgaris, bacterial skin diseases) located at places of the body, which potentially are possible to be used for localisation of the glucose sensor) Subject is currently abusing illicit drugs Subject is currently abusing prescription drugs Subject is currently abusing alcohol Subject is using pramlintide (Symlin) at time of screening Subject has elective surgery planned that requires general anaesthesia during

2015 Clinical Trials

30. Closed-loop Control of Postprandial Glucose Levels in Adults With Type 1 Diabetes

40 ml/min), neuropathy (especially diagnosed gastroparesis) or severe proliferative retinopathy as judged by the investigator. Recent (< 3 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery. Ongoing pregnancy. Severe hypoglycemic episode within 1 month of screening. Agents affecting gastric emptying (Motilium®, Prandase®, Victoza®, Byetta® and Symlin®) as well as oral anti-diabetic agents (Metformin, SGLT-2 inhibitors and DPP-4 inhibitors) if not at a stable dose

2015 Clinical Trials

31. Hybrid Closed Loop Pivotal Trial in Type 1 Diabetes

of the study Actively participating in an investigational study (drug or device) wherein he/she has received treatment from an investigational study drug or investigational study device in the last 2 weeks Has been hospitalized or has visited the ER in the 6 months prior to screening resulting in a primary diagnosis of uncontrolled diabetes Currently abusing illicit drugs Currently abusing marijuana. Currently abusing prescription drugs Currently abusing alcohol Using pramlintide (Symlin), DPP-4 inhibitor

2015 Clinical Trials

32. Closed-loop Control of Postprandial Glucose Levels in Children and Adults With Type 1 Diabetes

affecting gastric emptying (Motilium®, Prandase®, Victoza®, Byetta® and Symlin®) as well as oral anti-diabetic agents (Metformin, SGLT-2 inhibitors and DPP-4 inhibitors) if not at a stable dose for 3 months. Otherwise, these medications are acceptable and will be kept stable during the entire protocol. Oral steroids unless patients present a low stable dose (e.g. 10 mg or less of prednisone per day or physiological doses, less than 35 mg/day, of hydrocortisone Cortef®). Inhale steroids at stable dose

2015 Clinical Trials

33. Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus

: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Pramlintide acetate & regular insulin Pramlintide will be adiministered by sc infusion at a concentration of 1000ug/mL Drug: Pramlintide acetate Pramlintide acetate administered by a separate pump Other Name: Pramlintide: SYMLIN Drug: Lispro insulin U-100 Subjects will be stabilized on a separate insulin pump and administered lispro insulin throughout the study, except during both inpatient treatment periods (Visit 4 (...) procedures Female and/or male aged between 18 and 70 years Must have a prior diagnosis of T1DM Body mass index (BMI) <30 kg/m2 Subjects are not on current treatment with pramlintide (Symlin) and have not received pramlintide during the 6-month period prior to enrollment Subjects should be willing to consume all of the components of the standardized meals administered during the study Negative serum pregnancy test for female subjects of childbearing potential Female subjects of childbearing potential must

2015 Clinical Trials

34. The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes

percent (Diabetes Control and Complications Trial (DCCT)), both inclusive, by central laboratory analysis (Visit 1, screening) corresponding to 53-86 mmol/mol (International Federation of Clinical Chemistry (IFCC)) Exclusion Criteria: Prior use of glucagon-like peptide-1 (GLP-1) receptor agonist or dipeptidyl peptidase IV (DPPIV) inhibitors Use of any medication, which in the investigator's opinion could interfere with the glycaemic control (e.g. systemic corticosteroids, pramlintide (Symlin®

2014 Clinical Trials

35. Threshold Suspend in Pediatrics at Home

abusing illicit drugs Subject is currently abusing prescription drugs Subject is currently abusing alcohol Subject is using pramlintide (Symlin) at time of screening Subject has a sickle cell disease, hemoglobinopathy; or has received red blood cell transfusion or erythropoietin within 3 months prior to time of screening Subject plans to receive red blood cell transfusion or erythropoietin over the course of study participation Subject diagnosed with current eating disorder such as anorexia or bulimia

2014 Clinical Trials

36. Obesity (Treatment)

of their lives). Agents in early phases of investigation that may yet prove useful against obesity include the following: Ghrelin antagonists, Alpha–melanocyte-stimulating hormone analogs Enterostatin Neuropeptide YY antagonists Beta3-adrenergic agonists In addition, various nutraceuticals and herbal products have shown promise. For example, an extract from the African cactus Hoodia gordonii may cause clinically significant appetite suppression. The diabetes drug pramlintide (Symlin), which is a synthetic

2014 eMedicine.com

37. Diabetic Nephropathy (Treatment)

with kidney disease. Amylin analogs Amylin is a 37-amino acid peptide co-secreted by β cells with insulin and is deficient in diabetes. Its levels parallel insulin levels, and its actions are complementary to insulin in regulating plasma glucose concentration. Amylin slows gastric emptying, reduces postprandial glucagon, and can suppress appetite. Pramlintide (Symlin) is the only available amylin analog; it is given as an injection along with insulin therapy at meals. Dose adjustments for pramlintide

2014 eMedicine.com

38. Obesity (Follow-up)

of their lives). Agents in early phases of investigation that may yet prove useful against obesity include the following: Ghrelin antagonists, Alpha–melanocyte-stimulating hormone analogs Enterostatin Neuropeptide YY antagonists Beta3-adrenergic agonists In addition, various nutraceuticals and herbal products have shown promise. For example, an extract from the African cactus Hoodia gordonii may cause clinically significant appetite suppression. The diabetes drug pramlintide (Symlin), which is a synthetic

2014 eMedicine.com

39. Diabetic Nephropathy (Follow-up)

with kidney disease. Amylin analogs Amylin is a 37-amino acid peptide co-secreted by β cells with insulin and is deficient in diabetes. Its levels parallel insulin levels, and its actions are complementary to insulin in regulating plasma glucose concentration. Amylin slows gastric emptying, reduces postprandial glucagon, and can suppress appetite. Pramlintide (Symlin) is the only available amylin analog; it is given as an injection along with insulin therapy at meals. Dose adjustments for pramlintide

2014 eMedicine.com

40. Closed-loop Control of Glucose Levels After Meal Intake in Adults With Type 1 Diabetes

with the interpretation of the results because of their well known impact on gastric emptying: Motilium®, Prandase®, Victoza®, Byetta® and Symlin®. Known or suspected allergy to the trial products, meal contents including nuts, peanuts, dairy products or eggs. Unusual nutritional habits (e.g. vegetarians) Other serious medical illness likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator. Failure to comply with team's recommendations (e.g

2013 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>